These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 19882275)

  • 1. Target gene discovery for novel therapeutic agents in cancer treatment.
    Ammerpohl O; Tiwari S; Kalthoff H
    Methods Mol Biol; 2010; 576():427-45. PubMed ID: 19882275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Target Gene Discovery for Novel Therapeutic Agents in Cancer Treatment.
    Tiwari S; Ammerpohl O; Kalthoff H
    Methods Mol Biol; 2016; 1381():181-200. PubMed ID: 26667461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 3-aryl-5-aryl-1,2,4-oxadiazoles as a new series of apoptosis inducers. 2. Identification of more aqueous soluble analogs as potential anticancer agents.
    Kemnitzer W; Kuemmerle J; Zhang HZ; Kasibhatla S; Tseng B; Drewe J; Cai SX
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4410-5. PubMed ID: 19500976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An efficient synthesis and biological study of novel indolyl-1,3,4-oxadiazoles as potent anticancer agents.
    Kumar D; Sundaree S; Johnson EO; Shah K
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4492-4. PubMed ID: 19559607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical approaches to the discovery and development of cancer therapies.
    Neidle S; Thurston DE
    Nat Rev Cancer; 2005 Apr; 5(4):285-96. PubMed ID: 15803155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Turning promiscuous kinase inhibitors into safer drugs.
    Zhang X; Crespo A; Fernández A
    Trends Biotechnol; 2008 Jun; 26(6):295-301. PubMed ID: 18403035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of anticancer activity of buforin IIb, a histone H2A-derived peptide.
    Lee HS; Park CB; Kim JM; Jang SA; Park IY; Kim MS; Cho JH; Kim SC
    Cancer Lett; 2008 Nov; 271(1):47-55. PubMed ID: 18617323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo.
    Hu Y; Cherton-Horvat G; Dragowska V; Baird S; Korneluk RG; Durkin JP; Mayer LD; LaCasse EC
    Clin Cancer Res; 2003 Jul; 9(7):2826-36. PubMed ID: 12855663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. R-253 disrupts microtubule networks in multiple tumor cell lines.
    Gururaja TL; Goff D; Kinoshita T; Goldstein E; Yung S; McLaughlin J; Pali E; Huang J; Singh R; Daniel-Issakani S; Hitoshi Y; Cooper RD; Payan DG
    Clin Cancer Res; 2006 Jun; 12(12):3831-42. PubMed ID: 16778111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 5-(4-hydroxy-6-methyl-2-oxo-2H-pyran-3-yl)-7-phenyl-(E)-2,3,6,7-tetrahydro-1,4-thiazepines as a new series of apoptosis inducers using a cell- and caspase-based HTS assay.
    Drewe J; Kasibhatla S; Tseng B; Shelton E; Sperandio D; Yee RM; Litvak J; Sendzik M; Spencer JR; Cai SX
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4987-90. PubMed ID: 17562361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based virtual screening approach to identify novel classes of Cdc25B phosphatase inhibitors.
    Park H; Li M; Choi J; Cho H; Ham SW
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4372-5. PubMed ID: 19500977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies.
    Nobili S; Mini E; Landini I; Gabbiani C; Casini A; Messori L
    Med Res Rev; 2010 May; 30(3):550-80. PubMed ID: 19634148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is there a case for selectively promiscuous anticancer drugs?
    Fernández A; Crespo A; Tiwari A
    Drug Discov Today; 2009 Jan; 14(1-2):1-5. PubMed ID: 19038361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel peptide from alpha5 helix of Asterina pectinifera cyclin B conjugated to HIV-Tat(49-57) with cytotoxic and apoptotic effects against human cancer cells.
    Lou H; Gao Y; Zhai M; Qi Y; Chen L; Lv H; Yu J; Li Y
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4633-7. PubMed ID: 18656352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor.
    Maquoi E; Sounni NE; Devy L; Olivier F; Frankenne F; Krell HW; Grams F; Foidart JM; Noël A
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4038-47. PubMed ID: 15217936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis.
    Tyagi AK; Singh RP; Agarwal C; Chan DC; Agarwal R
    Clin Cancer Res; 2002 Nov; 8(11):3512-9. PubMed ID: 12429642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategy for the development of novel anticancer drugs.
    Saijo N; Tamura T; Nishio K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.